← PURPLE BIOTECH LTD. (PPBT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
PURPLE BIOTECH LTD. (PPBT)
Pharmaceutical Preparations · market cap $2M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
- 2027-01-01Phase 1imp 4/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NT219 | Phase 2 | Head and Neck Cancer |
Price & technical context
3-month
-10.6%
6-month
-64.6%
12-month
-74.1%
52-wk range
$0.83–$10.60
vs 50-day MA
-2.9%
vs 200-day MA
-58.1%
Realized vol
345.1%
Max drawdown
-99.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PPBT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.